This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
Edurant
INN: rilpivirine
Data updated: 2026-05-09
Available in:
🇨🇿🇩🇪🇬🇧🇵🇹🇸🇰🇹🇷
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Janssen-Cilag International N.V.
ATC Code
J05AG05
Source
EMA · EMEA/H/C/002264
(
ARTG
)
EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with viral load less than or equal to 100,000 copies/mL at baseline. This indication is based on Week 48 safety and efficacy analyses from 2 randomised double-blind, controlled Phase III trials in treatment-naive adult patients and on Week 96 safety and efficacy analyses from the Phase IIb trial TMC278-C204 in treatment-naive adult patients (see CLINICAL TRIALS section).
⚠️ Warnings
• Caution should be exercised in patients with history of kidney problems, irregular heartbeat, liver impairment, mental illness, suicidal thoughts, any allergy, who are taking other medications, elderly, children, during pregnancy and breastfeeding.
• It may cause dizziness, do not drive a car or operate machinery while taking this medication.
• It does not stop the spread of HIV to others; avoid sexual contact, sharing needles, injection supplies during the treatment period.
• Accumulation or loss of body fat may occur in some body parts; if it is so consult with your healthcare provider.
♦
Patient may develop Immune Reconstitution Syndrome and Depressive Disorders such as depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation.